Ativo Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Ativo Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-41,123	Closed	-$2.07M	–	223
2016 Q2	$2.07M	Sell	41,123 -144	-0.3%	-$7.67K	0.5%	57
2016 Q1	$2.21M	Sell	41,267 -167,767	-80%	-$9.84M	0.6%	60
2015 Q4	$13.7M	Buy	209,034 +27,020	+15%	+$1.67M	3.44%	3
2015 Q3	$10.8M	Buy	182,014 +16,073	+10%	+$1.04M	2.89%	3
2015 Q2	$11.7M	Sell	165,941 -18,602	-10%	-$1.15M	4.12%	1
2015 Q1	$11.5M	Buy	184,543 +2,040	+1%	+$119K	4.5%	2
2014 Q4	$10.5M	Sell	182,503 -25,781	-12%	-$1.44M	4.31%	2
2014 Q3	$11.2M	Buy	208,284 +63,411	+44%	+$3.36M	4.41%	1
2014 Q2	$7.59M	Buy	144,873 +45,433	+46%	+$2.32M	3.29%	2
2014 Q1	$5.25M	Buy	+99,440	New	+$4.6M	2.13%	7

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ativo Capital Management's TEVA Position: Q3 2016 in Review

Ativo Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2016, closing a stake of 41,123 shares — an estimated $2.07M sold.

Ativo Capital Management first reported a position in TEVA in Q1 2014 and held it in 10 quarters. The position peaked at $13.7M in Q4 2015. 795 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

Ativo Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Ativo Capital Management sold 41,123 Teva Pharmaceuticals shares in Q3 2016, an estimated $2.07M.
Ativo Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 10 quarters.
Ativo Capital Management's Teva Pharmaceuticals position peaked at $13.7M in Q4 2015.
795 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Ativo Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.